56 studies found for:    Open Studies | "Unrelated Donors"
Show Display Options
Rank Status Study
21 Recruiting Phase II Maraviroc for GVHD Prevention
Condition: Hematologic Malignancy Requiring Allogeneic Stem-cell Transplantation.
Intervention: Drug: Maraviroc 300 mg
22 Unknown  Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Condition: Hematopoietic/Lymphoid Cancer
Interventions: Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
23 Recruiting Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
Condition: Anemia, Aplastic
Intervention: Drug: Cyclophosphamide,Campath IH and TBI
24 Recruiting Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate;   Drug: bortezomib;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: melphalan;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: syngeneic bone marrow transplantation;   Other: laboratory biomarker analysis
25 Recruiting Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
Condition: Thalassemia
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Campath 1H;   Drug: Cyclophosphamide;   Drug: MESNA
26 Not yet recruiting Selective T Cell Depletion in Preventing Graft-Versus-Host Disease in Patients With Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, or Chronic Myelogenous Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Graft Versus Host Disease;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Relapsing Chronic Myelogenous Leukemia
Interventions: Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Drug: thiotepa;   Drug: cyclophosphamide;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: tacrolimus;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
27 Unknown  Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Condition: Leukemia
Interventions: Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: methotrexate;   Procedure: allogeneic hematopoietic stem cell transplantation
28 Recruiting Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)
Condition: Acute Lymphoid Leukemia
Intervention: Procedure: alloHCT
29 Recruiting HCT Versus CT in Elderly AML
Condition: Acute Myeloid Leukemia
Interventions: Procedure: hematopoietic cell transplantation;   Drug: Non-Transplant treatment approach for consolidation
30 Recruiting Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation
Conditions: Graft-versus-host Disease;   Survival
Interventions: Drug: Sirolimus/tacrolimus;   Drug: cyclosporine/methotrexate
31 Recruiting Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency
Condition: DOCK8 Deficiency
Interventions: Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Equine ATG;   Drug: Busulfan (Busulfex)
32 Recruiting Infusion of Depleted T Cells Following Transplant in Adults With Acute Leukaemia (ICAT)
Conditions: Acute Myeloid Leukaemia;   Acute Lymphoblastic Leukaemia
Intervention: Biological: CD25/71 allodepleted donor T-cells
33 Unknown  Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute Graft Versus Host Disease (aGVHD) During Transplant
Conditions: AML;   ALL;   Undifferentiated Leukemia;   Biphenotypic Leukemia;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts;   Refractory Anemia With Excess Blasts-1 (5-10% Blasts);   Refractory Anemia With Excess Blasts-2 (10-20% Blasts);   Myelodysplastic Syndrome, Unclassified;   MDS Associated With Isolated Del (5q)
Intervention: Drug: Abatacept
34 Recruiting Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia
Interventions: Drug: clofarabine;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Other: pharmacological study
35 Recruiting Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia
Interventions: Drug: fludarabine phosphate;   Biological: rituximab;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Other: pharmacological study
36 Recruiting Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression
Condition: Graft Versus Host Disease
Intervention: Drug: Tacrolimus and MMF.
37 Recruiting Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Conditions: MUD Transplant;   AlloPBSC;   Congenital Immunodeficiencies;   HLA Matched Transplant;   BMT
Interventions: Drug: Busulfan;   Drug: Campath-1 H;   Drug: Sirolimus;   Procedure: BMT;   Procedure: Apheresis;   Procedure: Total Body Irradiation;   Procedure: GCSF Injections
38 Recruiting Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) <= 60y. After First CR
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: Human Stem Cell Transplantation;   Drug: Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
39 Recruiting Evaluation of 3 Different Doses of IV Busulfan
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia
Interventions: Drug: BX2;   Drug: BX3;   Drug: BX4
40 Recruiting Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Conditions: Blood Stem Cell Transplant Failure;   Leukemia;   Hematologic Malignancies
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Procedure: Stem Cell Transplantation;   Drug: Thiotepa;   Drug: Tacrolimus;   Drug: Mycofenolate mofetil;   Drug: G-CSF

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-56) Show next page of results
Indicates status has not been verified in more than two years